<span>Story:::Bristol-Myers Squibb </span><span>:: document</span><span>Drugmakers plan to raise U.S. prices for at least 350 brand-name drugs in 2026, including vaccines and blockbuster cancer treatment Ibrance.</span><span>::CVS</span><span>That’s according to data provided exclusively to Reuters by medical research firm 3 Axis Advisors.</span><span>Prices are rising even as the Trump administration is pressuring drugmakers to cut production.</span><span>::CVS</span><span>The number of price increases increased year-over-year, while the median price increase of 4% was consistent with 2025.</span><span>These increases do not reflect any rebates and other discounts to pharmacy benefit managers.</span><span>:: Boehringer Ingelheim</span><span>The drugmaker also plans to lower list prices on about nine drugs, including diabetes treatment Jardiance, by as much as 40%.</span><span>It is one of 10 drugs the U.S. government has negotiated for lower prices in 2026 under the Medicare program for people 65 and older.</span><span>::Pfizer</span><span>One health policy researcher told Reuters the deals were heralded as transformative, but in fact they were actually just eating into the real reasons for high U.S. prescription drug prices.</span><span>::CVS</span><span>Currently, U.S. patients pay the most for prescription drugs, often nearly three times as much as in other developed countries.</span><span>Pfizer announced the largest list price increases for about 80 different drugs, including a 15% increase for cancer drug Ibrance and its COVID-19 vaccine.</span><span>::Pfizer</span><span>:: document</span><span>Pfizer said in a statement that it has adjusted the average list price of innovative medicines and vaccines in 2026 to be below the overall rate of inflation.</span><span>::CVS</span><span>More price hikes and cuts are expected in early January, the month with the most price increases by drugmakers in history.</span>
